ArticleDiscover oncology2025
Impact of tumor-to-nipple distance on outcomes in robotic nipple-sparing mastectomy and reconstruction.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNipple-sparing mastectomy (NSM) has become a preferred surgical option for breast cancer patients due to its oncologic safety and aesthetic benefits. Robotic NSM (RNSM) offers enhanced precision and minimally invasive access, yet its feasibility in cases with a tumor-to-nipple distance (TND) ≤ 1 cm remains unclear. This study evaluates the oncologic safety and surgical outcomes of RNSM in patients with TND ≤ 1 cm by comparing it with both RNSM in patients with TND > 1 cm and conventional NSM (CNSM) in patients with TND ≤ 1 cm.
methodsA retrospective analysis of 1427 patients who underwent NSM with immediate reconstruction between October 2020 and October 2023 was conducted. Propensity score matching (PSM) was applied to compare three groups: TND ≤ 1 cm, RNSM vs. TND > 1 cm, RNSM and TND ≤ 1 cm, RNSM vs. TND ≤ 1 cm, CNSM. Oncologic safety was assessed by analyzing subareolar resection margin status, while surgical outcomes included postoperative complications such as nipple-areolar complex (NAC) necrosis.
resultAfter PSM, no statistically significant differences were observed in subareolar resection margin results or the incidence of adverse events between the TND ≤ 1 cm and TND > 1 cm RNSM groups. Similarly, no significant differences were found in oncologic or surgical outcomes between RNSM and CNSM in patients with TND ≤ 1 cm.
conclusionsRNSM is a safe and feasible option for patients with TND ≤ 1 cm, achieving oncologic outcomes comparable to CNSM in patients with TND ≤ 1 cm and RNSM in patients with TND > 1 cm. These findings suggest that TND ≤ 1 cm should not be a contraindication for RNSM. Further prospective studies with long-term follow-up are necessary to validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.